Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The provided name conflates several distinct receptors (singular forms recommended), merges two receptor families, and uses a plural abbreviation without distinction between alpha/beta forms of PDGFRs. For clarity, each individual receptor should be treated as its own target; "PDGFRs" is incomplete. Vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and platelet-derived growth factor receptors (PDGFR-alpha, PDGFR-beta) are members of the receptor tyrosine kinase family essential for regulating blood vessel growth, maintenance, and lymphatic vessel development[1][3][4][5][8]. VEGFR-1 primarily modulates angiogenesis and the recruitment of monocytes; VEGFR-2 is the primary mediator of angiogenic signaling, promoting endothelial proliferation, migration, and vascular permeability[3][4][8]. VEGFR-3 is mainly involved in lymphangiogenesis. PDGFR-alpha and PDGFR-beta regulate mesenchymal cell proliferation and recruitment, vessel stabilization, and tissue maintenance[1][6]. Both VEGFRs and PDGFRs have extracellular ligand-binding domains, a transmembrane helix, and an intracellular split tyrosine kinase domain; activation leads to downstream signaling through pathways such as PI3K/AKT and MAPK[1][8]. Dysregulation or overactivation is implicated in pathological angiogenesis and numerous malignancies, making these receptors key therapeutic targets in anti-angiogenic and anti-tumor strategies[8]. While grouped in your query, each receptor should ideally be treated as an individual target according to best practices. "PDGFRs" must be resolved into "platelet-derived growth factor receptor alpha" and "platelet-derived growth factor receptor beta" for structured annotation.
Inhibition of ligand binding; Inhibition of receptor tyrosine kinase activity; Blocking angiogenic and/or lymphangiogenic signaling; Suppression of endothelial cell proliferation and migration; Induction of apoptosis in tumor vasculature; Disruption of downstream signaling such as PI3K/AKT and MAPK pathways
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VEGFR-1, VEGFR-2, VEGFR-3, PDGFRs.